-
1 Comment
Creso Pharma Limited is currently in a long term downtrend where the price is trading 14.0% below its 200 day moving average.
From a valuation standpoint, the stock is 88.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 30.3.
Creso Pharma Limited's total revenue sank by 63.5% to $994K since the same quarter in the previous year.
Its net income has dropped by 52.3% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 44.7% to $-3M since the same quarter in the previous year.
Based on the above factors, Creso Pharma Limited gets an overall score of 2/5.
Exchange | AU |
---|---|
CurrencyCode | AUD |
ISIN | AU000000CPH2 |
Sector | Healthcare |
Industry | Pharmaceuticals |
Market Cap | 23M |
---|---|
PE Ratio | None |
Target Price | None |
Dividend Yield | 0.0% |
Beta | 2.62 |
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and other health in Europe, Canada, Asia Pacific, the United States, and internationally. The company develops and commercializes therapeutic products; develops and sells beauty and personal care products under the Green Goo, Southern Butter, and Goodgoo brands; and cultivates, processes, and sells cannabis products. Its products include cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and minerals in a lozenge delivery system; the ImpACTIVE Pro Releaf Stick to provide relief to muscle aches, particularly in professional sport, and acts as an alternative to pharmacological solutions sold through online channels; Ritual Green, a dried flower; Ritual Sticks for pre-rolled joints; and Ritual Gold, a handheld vapouriser. In addition, the company develops Halucenex, which is in phase II clinical trials, which will test the efficacy of psilocybin on treatment of resistant Post Traumatic Stress Disorder. Further, it engages in marketing of its hemp based food, feed supplements, and topical products; manufacture and sale of packaged consumer products; conducts clinical trial and development of synthetic psilocybin micro and macro dose formulations to treat treatment resistant depression and anxiety; and development of psychedelic medicines. The company was incorporated in 2015 and is headquartered in Nedlands, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CPH.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025